Clinical trial
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
NCT05075577
Study timeline
Study start (actual)2021-12-21Date precision: day
Registry last updated2025-02-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
EnzalutamideDRUG · verified · RxNorm: enzalutamide
Sponsors & collaborators
ESSA Pharmaceuticalslead sponsor
Mapped research locations
BaltimoreMaryland, United States2MontrealQuebec, Canada2BuffaloNew York, United States2CalgaryAlberta, Canada2New YorkNew York, United States1St LouisMissouri, United States1TorontoOntario, Canada1TampaFlorida, United States1PortlandOregon, United States1OmahaNebraska, United States1TucsonArizona, United States1MadisonWisconsin, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05075577 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.